Xbrane Biopharma AB · OMXSTO:XBRANE

Xbrane Biopharma AB — Investor Presentation (April 2026)

15 slides from Xbrane Biopharma AB's investor presentation, April 2026

  1. Slide 1: Company Presentation

    STO: XBRANE April 2026 Company Presentation 1

  2. Slide 2: Important information

    Important information You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in

  3. Slide 3: Biosimilars are follow-on products to biologics, launched post patent expiry

    Biosimilars are follow-on products to biologics, launched post patent expiry Pharmaceuticals Small Molecules Biologics → 60% of global market, 1-3% p.a. growth1 → 40% of global market, 10-15% p.a. growth2 → Produced via chemical synthesis → Produced via recombinant DNA technology → Followed on by id

  4. Slide 4: Xbrane has a derisked late-stage biosimilar portfolio set to generate profitability

    Xbrane has a derisked late-stage biosimilar portfolio set to generate profitability Biosimilar candidate Ximluci® (ex-US) Lucamzi (US) Xdivane Reference product Therapeutic area Ophthalmology Oncology Dec 2028 (US) Patent expiry 2022 (EU) 2020 (US) June 2030 (EU) Development phase Commercial (Europe

  5. Slide 5: Ximluci launched in 24 countries by partner STADA. Xbrane get 50% of profit

    Ximluci® launched in 24 countries by partner STADA. Xbrane get 50% of profit Ximluci® launched by STADA in 24 countries Co-Development & Commercialization Partnership with STADA Partnership with STADA signed in 2018. STADA are granted the commercial rights to Ximluci® globally → Global generics and

  6. Slide 6: Ximluci addressable market in Europe is €5 billion

    Ximluci® addressable market in Europe is €5 billion Europe retinal anti VEGF: EUR 5 billion market Commentary → Europe retinal anti VEGF market at approx. €5 billion in € 5 billion 2025 with approx. 7 billion units (excl off label Avastin) 100% shipped Avastin (off-label) → Volume growth of 7% p.a.

  7. Slide 7: Ximluci has captured 8% ranibizumab volume market share in Europe

    Ximluci® has captured 8% ranibizumab volume market share in Europe Profit split to Xbrane and growth in vials sold by STADA Commentary → Volume constant Q4 2025 vs. Q3 2025. 140.0 100% → Ximluci® share of ranibizumab market across 120.0 113.7 115.7 114.9 115.8 launched countries in Europe was 8% by

  8. Slide 8: Lucamzi addressable market in the US €9 billion

    Lucamzi addressable market in the US €9 billion US retinal anti VEGF: EUR 9 billion market Commentary → Lucentis biosimilars covered under Medicare Part B with 20% patient co-payment € 9 billion 100% Avastin (off-label) → Reimbursement based on ASP* + 6-8% of originator ASP 80% Vabysmo → Dynamic whi

  9. Slide 9: Lucamzi - BLA re-submission planned for April/May 2026

    Lucamzi - BLA re-submission planned for April/May 2026 Xbrane & STADA partner with Valorum US Commercialization Partnership Xbrane and STADA license US commercial rights to Valorum Biologics. Valorum will be responsible for sales, → Biosimilar commercialization marketing and commercial efforts in th

  10. Slide 10: Xdivane is one out of five nivolumab biosimilars in clinic

    Xdivane is one out of five nivolumab biosimilars in clinic targeting $14b of expected originator sales Opdivo® expected to generate net-sales of $14b globally in 2028 Landscape & Commentary → Opdivo is an immuno-oncology drug (PD1 inhibitor) used in treatment of several cancers including melanoma an

  11. Slide 11: Xdivane is partnered with Intas/Accord with a 30% market share in oncology injectables in Europe

    Xdivane is partnered with Intas/Accord with a 30% market share in oncology injectables in Europe Partnership with Intas Global License & Co-Development Agreement Exclusive agreement with Intas signed in 2024. Intas will finance and oversee clinical and regulatory development activities as well as gl

  12. Slide 12: Xdivane clinical trial initiated and program on track towards day 1 launch

    Xdivane clinical trial initiated and program on track towards day 1 launch 2024 2025 2026 2027 2028 2029 2030 Commercialization Milestone payment to Milestone payment to Xbrane Xbrane LoE US LoE Europe Production of clinical material Pivotal clinical trial MAA / BLA → Successful scale-up to → Single

  13. Slide 13: Xdivane could generate SEK 1 billion in annual profit sharing

    Xdivane could generate SEK 1 billion in annual profit sharing, assuming historic oncology biosimilar penetration and price patterns US biosimilar volume market share vs. reference product Commentary → Oncology biosimilars have been well received with average penetration of 75% at year 3 post launch

  14. Slide 14: Xbrane on path towards full year profitability with stabilized balance sheet

    Xbrane on path towards full year profitability with stabilized balance sheet Historical Revenue Split and P&L Commentary → Ximluci product sales and profit sharing recognized upon P&L Overview (SEK, million) 2023A 2024A 2025A shipment of product to Stada (hence variability) License revenues 28.4 132

  15. Slide 15: Investment highlights

    Investment highlights Profitable • Ximluci® Europe/MENA income generation expected to cover fixed cost Ximluci ex. US base post ongoing production cost reduction measures base business • Further potential to increase market share • XdivaneTM on timeline towards US approval Q4 2028 and subsequent SEK

Xbrane Biopharma — Investor Presentation (April 2026) on 6ix